Literature DB >> 24217154

The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.

J Boysen1, S Sinha1, T Price-Troska1, S L Warner2, D J Bearss2, D Viswanatha1, T D Shanafelt1, N E Kay1, A K Ghosh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24217154      PMCID： PMC3929965          DOI： 10.1038/leu.2013.298

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation.

Authors:  Giridhar Mudduluru; Heike Allgayer
Journal:  Biosci Rep       Date:  2008-06       Impact factor: 3.840

2.  Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.

Authors:  Mark Mackiewicz; Konrad Huppi; Jason J Pitt; Tiffany H Dorsey; Stefan Ambs; Natasha J Caplen
Journal:  Breast Cancer Res Treat       Date:  2011-08-04       Impact factor: 4.872

Review 3.  The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.

Authors:  N E Kay; S M O'Brien; A R Pettitt; S Stilgenbauer
Journal:  Leukemia       Date:  2007-06-14       Impact factor: 11.528

4.  A role for ATR in the DNA damage-induced phosphorylation of p53.

Authors:  R S Tibbetts; K M Brumbaugh; J M Williams; J N Sarkaria; W A Cliby; S Y Shieh; Y Taya; C Prives; R T Abraham
Journal:  Genes Dev       Date:  1999-01-15       Impact factor: 11.361

5.  Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

Authors:  Thorsten Zenz; Sonja Häbe; Tina Denzel; Julia Mohr; Dirk Winkler; Andreas Bühler; Antonio Sarno; Silja Groner; Daniel Mertens; Raymonde Busch; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2009-07-30       Impact factor: 22.113

6.  miR-34a as part of the resistance network in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Julia Mohr; Eric Eldering; Arnon P Kater; Andreas Bühler; Dirk Kienle; Dirk Winkler; Jan Dürig; Marinus H J van Oers; Daniel Mertens; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

7.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.

Authors:  Dmitri Lodygin; Valery Tarasov; Alexey Epanchintsev; Carola Berking; Tatjana Knyazeva; Henrike Körner; Piotr Knyazev; Joachim Diebold; Heiko Hermeking
Journal:  Cell Cycle       Date:  2008-08-01       Impact factor: 4.534

Review 8.  The miR-34 family in cancer and apoptosis.

Authors:  H Hermeking
Journal:  Cell Death Differ       Date:  2009-05-22       Impact factor: 15.828

9.  Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner.

Authors:  Atsushi Hirao; Alison Cheung; Gordon Duncan; Pierre-Marie Girard; Andrew J Elia; Andrew Wakeham; Hitoshi Okada; Talin Sarkissian; Jorge A Wong; Takashi Sakai; Elisa De Stanchina; Robert G Bristow; Toshio Suda; Scott W Lowe; Penny A Jeggo; Stephen J Elledge; Tak W Mak
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

10.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.

Authors:  Tsung-Cheng Chang; Erik A Wentzel; Oliver A Kent; Kalyani Ramachandran; Michael Mullendore; Kwang Hyuck Lee; Georg Feldmann; Munekazu Yamakuchi; Marcella Ferlito; Charles J Lowenstein; Dan E Arking; Michael A Beer; Anirban Maitra; Joshua T Mendell
Journal:  Mol Cell       Date:  2007-05-31       Impact factor: 17.970
View more
  22 in total

Review 1.  MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.

Authors:  K Musilova; M Mraz
Journal:  Leukemia       Date:  2014-12-26       Impact factor: 11.528

2.  Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.

Authors:  Sutapa Sinha; Justin Boysen; Michael Nelson; Charla Secreto; Steven L Warner; David J Bearss; Connie Lesnick; Tait D Shanafelt; Neil E Kay; Asish K Ghosh
Journal:  Clin Cancer Res       Date:  2015-02-11       Impact factor: 12.531

3.  Aberrant microRNA expression in tumor mycosis fungoides.

Authors:  E Papadavid; M Braoudaki; M Bourdakou; A Lykoudi; V Nikolaou; G Tounta; A Ekonomidi; E Athanasiadis; G Spyrou; C Antoniou; S Kitsiou-Tzeli; D Rigopoulos; A Kolialexi
Journal:  Tumour Biol       Date:  2016-09-13

4.  Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.

Authors:  S Sinha; J Boysen; M Nelson; S L Warner; D Bearss; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2015-11-24       Impact factor: 11.528

5.  Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.

Authors:  Neil E Kay; Traci Sassoon; Charla Secreto; Sutapa Sinha; Tait D Shanafelt; Asish K Ghosh; Jack L Arbiser
Journal:  Leuk Lymphoma       Date:  2016-05-17

6.  Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.

Authors:  J S Waizenegger; I Ben-Batalla; N Weinhold; T Meissner; M Wroblewski; M Janning; K Riecken; M Binder; D Atanackovic; H Taipaleenmaeki; D Schewe; S Sawall; V Gensch; M Cubas-Cordova; A Seckinger; W Fiedler; E Hesse; N Kröger; B Fehse; D Hose; B Klein; M S Raab; K Pantel; C Bokemeyer; S Loges
Journal:  Leukemia       Date:  2014-08-08       Impact factor: 11.528

7.  Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.

Authors:  Viralkumar Patel; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2015-11-16

8.  SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis.

Authors:  Guru P Maiti; Sutapa Sinha; Hasan Mahmud; Justin Boysen; Mariana T Mendez; Sara K Vesely; Jennifer Holter-Chakrabarty; Neil E Kay; Asish K Ghosh
Journal:  Blood Cancer J       Date:  2021-05-17       Impact factor: 11.037

9.  Discovery of a Novel Immune Gene Signature with Profound Prognostic Value in Colorectal Cancer: A Model of Cooperativity Disorientation Created in the Process from Development to Cancer.

Authors:  Ning An; Xiaoyu Shi; Yueming Zhang; Ning Lv; Lin Feng; Xuebing Di; Naijun Han; Guiqi Wang; Shujun Cheng; Kaitai Zhang
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

10.  The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels.

Authors:  Helena K Fritz; Anna Gustafsson; Börje Ljungberg; Yvonne Ceder; Håkan Axelson; Björn Dahlbäck
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.